Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Roivant Sciences Ltd. insider trading report: CEO and director Matthew Gline reported multiple transactions in Roivant common shares on 12/15/2025. He exercised stock options to buy 234,096 shares at $4.06 and a total of 3,636,563 shares at $12.68, then reported sales of 230,357, 566,116 and 943,527 shares at $21.68 per share. Additional share dispositions reflect “net settlement” of options to cover exercise prices. After these transactions, he reported beneficial ownership of 17,287,081 common shares held directly.
The filing notes that all options expiring in 2026 were exercised, eliminating that option position, and states that Gline has disgorged to Roivant the full amount of disgorgable profits from the sales as required by Section 16(b) of the Exchange Act.
Roivant Sciences director Vivek Ramaswamy reported large stock option exercises and related share sales in December 2025. On 12/11, 12/12 and 12/15, he exercised options at $12.68 per share to acquire 1,869,691, 4,672,724 and 832,453 common shares, respectively. On those same dates he sold 774,142, 1,975,858 and 353,745 shares at weighted average prices of $21.64, $21.96 and $22.05, and additional shares were disposed of through issuer net settlement to cover option exercise costs.
After these transactions, he beneficially owned 33,653,755 common shares directly and 13,357,857 shares indirectly through his spouse. The exercised options would have expired in March 2026 if not exercised and arise from awards that began vesting on December 27, 2019.
Immunovant, Inc. reported an insider transaction by a reporting person who is both a director and a 10% owner. On December 12, 2025, this filer purchased 16,666,666 shares of Immunovant common stock at $21 per share. Following the transaction, the filer directly beneficially owned 113,317,007 Immunovant shares. The filer is considered a director by deputization because senior executives of Roivant Sciences, Inc., a subsidiary of the reporting person, currently serve on Immunovant’s board on its behalf.
Roivant Sciences Ltd. officer Eric Venker, President & Immunovant CEO, reported equity transactions dated December 9, 2025. He exercised stock options to acquire 200,000 common shares at an exercise price of $3.85 per share, then sold 200,000 common shares at a weighted average price of $20.85 per share pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
After these transactions, he directly beneficially owned 1,497,908 common shares of Roivant Sciences. He also held 5,876,523 stock options exercisable into common stock at $3.85 per share, from a grant with a vesting commencement date of April 20, 2022 that vests 25% on the first anniversary and the remainder in 36 equal monthly installments, with an expiration date of April 19, 2032.
Roivant Sciences Ltd. (ROIV) reported an insider equity transaction by its Chief Financial Officer. On 11/20/2025, the CFO had 1,235 common shares withheld at a price of $20.27 per share. This was a "net settlement" of previously granted restricted stock units (RSUs) to cover tax withholding obligations when those RSUs vested and were settled.
After this tax-related share withholding, the CFO beneficially owns 388,273 common shares, held directly. The filing indicates this was an administrative equity compensation event, not an open-market purchase or sale.
Roivant Sciences Ltd. insider transaction: A Form 4 reports that officer Eric Venker, President & Immunovant CEO, had 7,051 common shares of Roivant Sciences Ltd. withheld on 11/20/2025 at a price of $20.27 per share. The filing explains this was a "net settlement" of previously granted restricted stock units (RSUs) by the company to cover applicable tax withholding when those RSUs vested and settled.
After this tax-related share withholding, Venker directly beneficially owns 1,497,908 common shares of Roivant Sciences Ltd. This type of transaction does not represent an open-market sale, but rather an administrative step tied to equity compensation vesting.
Roivant Sciences Ltd. (ROIV) director reported multiple indirect sales of common shares on 11/19/2025. The transactions were coded as open-market sales, with blocks of shares sold at prices between $20.16 and $20.25 per share through QVT Financial Investment Cayman Ltd.
Following these sales, the reporting person shows 18,047,727 Roivant common shares beneficially owned on an indirect basis through QVT Financial Investment Cayman Ltd. The filing notes that the individual is a shareholder of that entity but has no voting or investment control over it and expressly disclaims beneficial ownership of the reported shares beyond any pecuniary interest.
Roivant Sciences Ltd. (ROIV) director Dan Gold reported several open‑market sales of the company’s Common Shares on 11/19/2025. Indirectly through QVT Financial Investment Cayman Ltd., he sold 850,000 shares at $20.25, 150,000 shares at $20.20, 125,000 shares at $20.16, and 175,000 shares at $20.24, all coded as sales. Following these transactions, 18,047,727 Common Shares were beneficially owned indirectly, reported as held by QVT Financial Investment Cayman Ltd. The filing notes that Gold is one of three directors of QVT Financial Investment Cayman Ltd., shares voting and investment control over these shares, and disclaims beneficial ownership beyond his pecuniary interest.
Roivant Sciences Ltd. (ROIV) filed a Form 4 showing a significant shareholder-related sale of common shares. On 11/19/2025, an entity associated with QVT sold a total of 1,300,000 Roivant common shares in four open-market transactions at prices between $20.16 and $20.25 per share. After these sales, 18,047,727 common shares were reported as beneficially owned indirectly through QVT Financial Investment Cayman Ltd.
The explanation notes that QVT Financial LP and its related entities may be deemed to beneficially own 28,081,635 Roivant common shares in aggregate through several affiliated vehicles. QVT states that it disclaims beneficial ownership of these shares except to the extent of any pecuniary interest.
Roivant Sciences Ltd. director and more-than-10% owner Vivek Ramaswamy reported multiple open-market sales of the company’s common shares. On 11/13/2025 he sold 287,283 shares at a weighted average price of $20.81, on 11/14/2025 he sold 1,027,670 shares at a weighted average of $20.33, and on 11/17/2025 he sold 539,650 shares at a weighted average of $20.51. The prices reflect multiple individual trades within stated ranges for each day. After these transactions, he beneficially owned 33,653,756 common shares directly and 13,357,857 common shares indirectly through his spouse.